This Week in Peptide Research: A Kisspeptin Reproductive-Axis Cluster, Survodutide's Liver Mechanism, and Teriparatide's Cost Question

Peptide Science Daily reviewed new PubMed listings for its tracked compounds from August 2 through August 8, 2026. Two JAMA phase 3 trials of mazdutide and orforglipron also posted this week and already received dedicated coverage in a separate article; they are not repeated here. Beyond those, four threads stood out: a cluster of papers on kisspeptin and reproductive-axis signaling, a mechanistic dive into how the investigational drug survodutide helps the liver, a multi-drug safety review of GLP-1 receptor agonists in dialysis patients, and two contrasting looks at the bone-building peptide teriparatide, one on effectiveness and one on cost.

Four papers this week concerned kisspeptin, an investigational peptide hormone with an established role in reproductive neuroendocrinology but no approved therapeutic use. In the European Journal of Endocrinology, a study titled 'Chronic subcutaneous kisspeptin-10 stimulates gonadotropin secretion for 12 days in healthy men' tested three dosing protocols in a total of 15 healthy men: an acute dose-response phase found luteinizing hormone, follicle-stimulating hormone, and testosterone all rose with dose (p<.0001), but a continuous 5-day infusion caused the gonadotropin response to fade back to baseline, a phenomenon known as tachyphylaxis, even though testosterone stayed elevated. Switching to a 12-day intermittent dosing schedule avoided this fade: mean luteinizing hormone rose significantly on both day 1 and day 12 of dosing (p=.003 versus vehicle on day 12), suggesting intermittent rather than continuous delivery may be needed to sustain the hormonal effect. In Clinical Endocrinology, a study of 50 men divided by semen quality, 'Seminal Plasma Kisspeptin-1 and Kisspeptin-54 Levels Are Associated With Semen Parameters and Oxidative Stress in Male Infertility,' reported that both kisspeptin forms declined progressively from normal semen quality through moderate infertility to azoospermia, correlated positively with sperm concentration and motility, and correlated negatively with oxidative stress markers (p<.01), leading the authors to propose seminal kisspeptin as a candidate biomarker for infertility evaluation, pending further validation. A systematic review in Behavioural Brain Research, 'Neurotransmitter and neuromodulator imbalance in kisspeptin/GnRH regulation in rodent models of polycystic ovary syndrome and its implications for mental health disorders,' compared three rat and mouse PCOS models and found each disrupted kisspeptin-driven signaling to the brain's reproductive-hormone neurons differently depending on how PCOS was induced; the authors proposed that reproduction and mood may share underlying neural mechanisms in PCOS but stated this remains unconfirmed in human patients. Separately, in Biochimica et Biophysica Acta - Molecular Basis of Disease, a rat and cell-culture study, 'Stigmasterol alleviates central precocious puberty by targeting the IGF-1/PI3K/Akt/mTOR signaling pathway and modulating the Kisspeptin/GnRH axis,' reported that the plant-derived compound stigmasterol delayed premature sexual development in a chemically induced rat model of early puberty, an effect the authors linked partly to changes in kisspeptin/GnRH axis gene and protein expression. Stigmasterol itself is not a peptide and has no approved role in treating precocious puberty in humans; the finding is preclinical.

On the metabolic side, a mediation analysis of a phase 2 trial (NCT04771273) published in Hepatology, 'Weight reduction-dependent/-independent effects of survodutide on liver endpoints,' examined 48-week outcomes in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis. It reported that survodutide's benefit on liver fibrosis and inflammation was predominantly independent of how much weight patients lost, which the authors said points to a direct effect of glucagon receptor agonism on the liver, while its effect on liver fat content as measured by FibroScan was largely explained by weight loss (about 77% mediated). Survodutide remains investigational, with no marketing approval from the FDA, the EMA, or Australia's TGA. Separately, in Endocrine Practice, a systematic review and meta-analysis, 'Safety and efficacy of glucagon like peptide-1 receptor agonism-based therapies in end-stage renal disease,' pooled 19 studies covering 388 patients on dialysis or with advanced kidney disease, most of them on semaglutide (266 patients) with smaller numbers on liraglutide, dulaglutide, and tirzepatide. It reported weight loss of roughly 3 to 7 kilograms and HbA1c reductions of 0.5 to 0.75 percentage points with semaglutide over 3 to 12 months, alongside gastrointestinal adverse events in about 39% of semaglutide-treated patients; the review authors described their findings as hypothesis-generating given the small, largely non-randomized dataset, and called for prospective randomized trials before drawing firm conclusions about GLP-1 drugs in this population.

Two papers this week concerned teriparatide, an FDA-approved anabolic bone peptide, from opposite angles. A network meta-analysis in the European Journal of Endocrinology, conducted on behalf of the European Calcified Tissue Society's Clinical Action Group, 'Effectiveness of Anti-Osteoporotic Medications in the Management of Glucocorticoid-Induced Osteoporosis,' pooled 31 studies covering 5,260 participants and reported that teriparatide produced larger lumbar-spine bone-density gains than alendronate, risedronate, denosumab, and zoledronate in this patient population, while among antiresorptive drugs zoledronate and denosumab outperformed oral bisphosphonates. The authors framed the results as supporting risk-based treatment selection rather than a single preferred drug. A separate systematic review in Clinical Drug Investigation, 'Cost Effectiveness of Teriparatide for Postmenopausal Osteoporosis,' examined 22 economic evaluations through October 2024 and concluded that teriparatide is generally not cost-effective for postmenopausal osteoporosis under typical willingness-to-pay thresholds, except in scenarios involving reduced drug prices, generic alternatives, or specific sensitivity-analysis assumptions; the authors noted most studies compared teriparatide against bisphosphonates or denosumab and that few accounted for indirect costs.

Three smaller items covered drug delivery, real-world outcomes, and a clinical case series rather than new therapeutic findings. In Discover Nano, a rat study, 'Antibiotic loaded solid lipid nanoparticles target bacteria in a pyogenic spondylitis rat model,' coated ampicillin-loaded nanoparticles with the antimicrobial peptide LL-37 to improve bacterial targeting, and reported that the LL-37-coated version reduced bacterial burden and improved outcomes in a rat model of spinal bone infection compared with free ampicillin. LL-37 remains investigational with no approved human indication. In the Hellenic Journal of Nuclear Medicine, a retrospective single-institution review of 32 neuroendocrine tumor patients over 10 years of peptide receptor radionuclide therapy (PRRT) with octreotide-based radiopharmaceuticals reported disease progression in 28%, stable disease in 50%, and partial remission in 22%, with time to progression roughly half as long in the progression group as in the others, and only mild to moderate toxicity. Finally, in The Mental Health Clinician, a four-patient case series, 'Secretagogue laxatives as a potential strategy to overcome adherence barriers to over-the-counter treatment for clozapine-induced constipation,' described using linaclotide or lubiprostone as an alternative when psychiatric patients on clozapine could not adhere to standard over-the-counter laxative regimens, a small clinical observation rather than a controlled trial.

None of this week's papers describe a newly completed pivotal human efficacy trial beyond the JAMA-published GLORY-2 and ACHIEVE-5 trials covered separately. Most of this week's findings come from a mechanistic mediation analysis, a small human dosing study, a retrospective single-institution review, two meta-analyses of existing trial and observational data, a case series, and animal or cell-culture research. Kisspeptin, survodutide, and LL-37 remain investigational with no approval from the FDA, the EMA, or Australia's TGA. As with all research covered here, these are findings a given study reported, not established clinical fact or treatment guidance.